Intelligent cell-based therapies for cancer and autoimmune disorders

被引：8
作者：
Chen, Rui [1 ]
Jing, Ji [1 ]
Siwko, Stefan [1 ]
Huang, Yun [2 ,3 ]
Zhou, Yubin [1 ,3 ]
机构：
[1] Texas A&M Univ, Ctr Translat Canc Res, Inst Biosci & Technol, Houston, TX 77030 USA
[2] Texas A&M Univ, Ctr Epigenet & Dis Prevent, Inst Biosci & Technol, Houston, TX 77030 USA
[3] Texas A&M Univ, Coll Med, Dept Translat Med Sci, Houston, TX 77030 USA
来源：
CURRENT OPINION IN BIOTECHNOLOGY | 2020年 / 66卷
关键词：
T-CELLS; TARGETED THERAPY; IMMUNOTHERAPY; SWITCH;
D O I：
10.1016/j.copbio.2020.08.012
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Synthetic biology, when combined with immunoengineering (designated synthetic immunology), has enabled the invention of an arsenal of genetically encoded synthetic devices and systems to reprogram cells for therapeutic purposes. The engineered intelligent cells can serve as 'living' drugs to treat a wide range of human diseases including cancer, disorders of the immune system, and infectious diseases. As the most successful example, cells of the immune system engineered with chimeric antigen receptors (CARs) have shown curative potentials for the treatment of hematological malignancies. We present herein emerging approaches of designing smart CARs to improve their safety, specificity and efficacy in cellular immunotherapy, and describe latest advances in applying CAR-engineered immune cells to target cancer and autoimmune diseases.
引用
收藏
页码：207 / 216
页数：10
相关论文
共 50 条
  • [21] Novel perspectives on dendritic cell-based immunotherapy of cancer
    Bonaccorsi, Irene
    Pezzino, Gaetana
    Morandi, Barbara
    Ferlazzo, Guido
    IMMUNOLOGY LETTERS, 2013, 155 (1-2) : 6 - 10
  • [22] Engineering approaches for RNA-based and cell-based osteoarthritis therapies
    DeJulius, Carlisle R.
    Walton, Bonnie L.
    Colazo, Juan M.
    d'Arcy, Richard
    Francini, Nora
    Brunger, Jonathan M.
    Duvall, Craig L.
    NATURE REVIEWS RHEUMATOLOGY, 2024, 20 (02) : 81 - 100
  • [23] Cell-based therapies: careful safety assessment for minimization of risk
    Comoli, Patrizia
    CYTOTHERAPY, 2010, 12 (06) : 710 - 712
  • [24] Accelerating Diverse Cell-Based Therapies Through Scalable Design
    Peterman, Emma L.
    Ploessl, Deon S.
    Galloway, Kate E.
    ANNUAL REVIEW OF CHEMICAL AND BIOMOLECULAR ENGINEERING, 2024, 15 : 267 - 292
  • [25] Vector Strategies to Actualize B Cell-Based Gene Therapies
    Jeske, Amanda M.
    Boucher, Paul
    Curiel, David T.
    Voss, James E.
    JOURNAL OF IMMUNOLOGY, 2021, 207 (03) : 755 - 764
  • [26] Prospects of apoptotic cell-based therapies for transplantation and inflammatory diseases
    Saas, Philippe
    Kaminski, Sandra
    Perruche, Sylvain
    IMMUNOTHERAPY, 2013, 5 (10) : 1055 - 1073
  • [27] Building with intent: Technologies and principles for engineering mammalian cell-based therapies to sense and respond
    Muldoon, Joseph J.
    Donahue, Patrick S.
    Dolberg, Taylor B.
    Leonard, Joshua N.
    CURRENT OPINION IN BIOMEDICAL ENGINEERING, 2017, 4 : 127 - 133
  • [28] IN VITRO POTENCY ASSAYS TO ASSESS THE FUNCTION OF CELL-BASED THERAPIES
    Pentakota, K.
    Montelongo, S.
    Beddard, R.
    Jones, S.
    Srinivasan, A.
    CYTOTHERAPY, 2023, 25 (06) : S202 - S203
  • [29] Engineering cell-based therapies to interface robustly with host physiology
    Schwarz, Kelly A.
    Leonard, Joshua N.
    ADVANCED DRUG DELIVERY REVIEWS, 2016, 105 : 55 - 65
  • [30] Gene-modified, cell-based therapies-an overview
    Powell, Allison B.
    Williams, Kiara
    Cruz, Conrad Russelly
    CYTOTHERAPY, 2016, 18 (11) : 1351 - 1359
12345